Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Times Interest Earned (2019 - 2022)

Keros Therapeutics (KROS) has disclosed Times Interest Earned for 4 consecutive years, with -$24126.0 as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Times Interest Earned fell 53.0% year-over-year to -$24126.0, compared with a TTM value of -$114790.0 through Dec 2022, down 714.5%, and an annual FY2022 reading of -$114790.0, down 714.5% over the prior year.
  • Times Interest Earned was -$24126.0 for Q1 2022 at Keros Therapeutics, down from -$4866.0 in the prior quarter.
  • Across five years, Times Interest Earned topped out at -$775.33 in Q3 2019 and bottomed at -$24126.0 in Q1 2022.
  • Average Times Interest Earned over 4 years is -$9955.0, with a median of -$8444.0 recorded in 2020.
  • The sharpest move saw Times Interest Earned tumbled 723.39% in 2020, then soared 63.39% in 2021.
  • Year by year, Times Interest Earned stood at -$775.33 in 2019, then crashed by 1614.23% to -$13291.0 in 2020, then skyrocketed by 63.39% to -$4866.0 in 2021, then plummeted by 395.81% to -$24126.0 in 2022.
  • Business Quant data shows Times Interest Earned for KROS at -$24126.0 in Q1 2022, -$4866.0 in Q4 2021, and -$20197.0 in Q3 2021.